HCV Video Perspectives

In this video, Robert S. Brown, Jr., MD, MPH, Gladys and Roland Harriman Professor of Medicine and clinical chief in the division of gastroenterology & hepatology at Weill Cornell Medicine, discusses:

• recent advances in HCV treatment, such as the approval of an 8-week regimen for glecaprevir/pibrentasvir (Mavyret; AbbVie) in treatment-naïve, chronic hepatitis C patients, without cirrhosis or with compensated cirrhosis;
• shorter duration treatment regimens of once-daily, all-oral therapy;
• the newer generations of all-oral therapy that work across all genotypes;
• the use of pangenotypic therapy in his practice and the therapies for certain patient subsets, such as Child-Pugh B and C, advanced renal disease, and decompensated cirrhosis;
• challenges standing in the way of achieving WHO’s goal to eliminate HCV by 2030 in the U.S.;
• the biggest areas of unmet needs in HCV, including screening, linkage to care for all patients identified, and the increasing rate of new infections and re-infections in people using opioids.